Lymphocyte antigen 75 (LY75)

Lymphocyte antigen 75 (LY75 or CD205) is a transmembrane endocytic receptor highly expressed by dendritic cells, where it facilitates the uptake and presentation of antigens for immune surveillance. Structurally, it is a member of the C-type lectin family, characterized by carbohydrate binding capacity, and primarily localizes to antigen-presenting compartments. The molecule is notable for its role in cross-presentation, making it a promising target for therapeutic approaches especially in cancer immunotherapy, as antibody-drug conjugates and vaccine adjuvants exploiting LY75 enhance immune recognition of tumors. LY75 is also implicated in immune regulation, inflammatory response, and some infectious and autoimmune diseases[2][3][5][9].

Other names

CD205DEC-205CLEC13BGP200-MR6Ly-75C-type lectin domain family 13 member Blymphocyte antigen 75

Antibody-drug conjugate binding to CD205 followed by cytotoxic payload delivery; Immune cell targeting via antigen uptake and cross-presentation by dendritic cells (used in cancer vaccines)